Bliss GVS Pharma falls 4.4% as Anupam Rasayan takes control and MD N.S. Kamath resigns

According to the September 28, 2026 filing (page 1), the board met "in relation to the consummation of the transaction" under the share purchase agreement dated May 23, 2026 between Anupam Rasayan India Limited (described as the "Purchaser"), the sellers including Mr. S. N. Kamath as Seller 1, and Mates Visa Consultancy Private Limited ("PAC") under a Deed of Adherence dated July 17, 2026.

The key outcome was a formal change in control and promoter status:

• The PAC completed the acquisition of 5,09,84,595 equity shares of Bliss GVS Pharma, representing 47.95% of the equity share capital as on the meeting date (page 1).
• Together with 1,669 equity shares acquired by the Purchaser under the open offer, Anupam Rasayan and PAC now collectively hold 5,09,86,264 equity shares, also described as 47.95% of the equity share capital (page 1).
• With effect from September 28, 2026, Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited "have acquired control of the Company" and "therefore have become the ‘Promoters’ of the Company" in line with SEBI regulations (page 1).

In other words, the filing confirms that the long-flagged transaction has now closed and the new owners are officially in the driver’s seat.

The market also had to digest a meaningful boardroom shake-up.

On page 2, the company discloses the resignation of Mr. Narsimha Shibroor Kamath from the position of Managing Director with effect from September 28, 2026. Annexure 4 (page 7) clarifies that the reason is "resignation pursuant to and in connection with completion of the transactions contemplated under the SPA." The resignation letter reproduced on pages 8–9 further states that it is being tendered "pursuant to and in connection with the completion of the transactions" and the "consequent change in control of the Company, including the transition of management and Board responsibilities." Mr. Kamath explicitly confirms "there are no other material reasons" for his resignation beyond those stated.

At the same meeting, the board inducted three new non-executive, non-independent directors with effect from September 28, 2026 (page 2):

• Mr. Hetul Krishnakant Mehta (DIN: 01650314) as Additional Director, Non-Executive Non-Independent.
• Mr. Amar Dilip Shah (DIN: 00214357) as Additional Director, Non-Executive Non-Independent.
• Mr. Pramod Badrinarayan Kasat (DIN: 00819790) as Additional Director, Non-Executive Non-Independent.

The annexures (pages 4–6) provide detailed profiles:

• Mr. Mehta is described as an entrepreneur with "over 30 years of experience in the pharmaceutical industry" and Managing Director of Praveen Laboratories Pvt. Ltd., with prior board experience at Anupam Rasayan India Limited.
• Mr. Shah is presented as an experienced business professional associated with Siyaram Silk Mills Limited, responsible for sales across Japan, India and USA and overseeing the P&L of a greenfield garment manufacturing unit.
• Mr. Kasat is a "seasoned Investment Banker" with "over three decades of experience" and cumulative deal experience "exceeding USD 5 billion," currently Managing Director of Intellecap.

The board also approved a draft postal ballot notice to seek shareholder approval for these appointments (page 2).

Crucially, the September 28 filing is a corporate actions document. It does not contain any revenue, profit, margin or guidance numbers, and it does not alter previously disclosed financials. The filing itself is silent on earnings, and it "does not break out margins" or any fresh outlook.

The live market read points out that for the quarter ended June 2026, Bliss GVS Pharma had already reported year-on-year growth in net profit and net sales. Those numbers are not part of the September 28 board outcome filing, so they do not directly explain Tuesday’s move.

Instead, the reaction appears to be about positioning and expectations:

• The stock had already gained over 380% in the year leading up to the announcement, according to market commentary. That kind of run-up often reflects investors buying ahead of a catalyst — in this case, the change of control and potential re-rating under a new promoter group.
• Once the deal was formally consummated and the board recorded the new promoters and MD exit, there was no incremental positive surprise in the filing: no new strategic roadmap, no fresh financial targets, and no sweetener beyond what the market already knew from earlier disclosures.
• In such situations, traders who bought on anticipation often "sell the news" — locking in profits when the long-awaited event finally becomes official.

The market read also notes that the broader healthcare index was trading higher on the day, and there were no reports of analyst downgrades or adverse sector-wide triggers. That suggests the 4.4% drop to Rs 705 was stock-specific and tied to the completion of the promoter transition rather than to any newly disclosed financial deterioration.

For investors trying to look beyond the knee-jerk reaction, it is just as important to note what the September 28 document does not cover:

• No details of any immediate operational changes, integration plans or strategic priorities under the new promoters.
• No commentary on capital allocation, product pipeline, or expansion plans.
• No updated financial guidance or margin commentary.

The filing is narrowly focused on regulatory compliance around the change in control, board composition and the Managing Director’s resignation. Any re-rating from here will likely depend on subsequent communications from Anupam Rasayan and PAC about how they intend to steer Bliss GVS Pharma.

For now, the stock’s move looks less like a verdict on fundamentals and more like a reset after a big pre-event rally, as the market shifts from speculating on the deal to waiting for the new promoters’ execution roadmap.